Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 7;14(2):183.
doi: 10.3390/jpm14020183.

Clinical Outcome of Multiple Platelet-Rich Plasma Injection and Correlation with PDGF-BB in the Treatment of Knee Osteoarthritis

Radiyati Umi Partan  1 , Khoirun Mukhsinin Putra  1 , Hafizzanovian Hafizzanovian  1 , Surya Darma  1 , Muhammad Reagan  1 , Putri Muthia  1 , Afifah Salshabila Radiandina  2 , Eny Rahmawati  3
Affiliations

Clinical Outcome of Multiple Platelet-Rich Plasma Injection and Correlation with PDGF-BB in the Treatment of Knee Osteoarthritis

Radiyati Umi Partan et al. J Pers Med. .

Abstract

(1) Background: Current treatments for knee osteoarthritis (KOA), such as intra-articular corticosteroids or hyaluronic acid (HA) injections, are controversial due to their ineffectiveness in preventing disease progression. Platelet-rich plasma (PRP) has become a promising and possible treatment for KOA. It is thought to enhance articular cartilage regeneration and reduce OA-related impairment. PRP contains growth factors such as PDGF-BB, which stimulates growth and inhibits joint damage. Based on numerous studies, after a certain amount of time, it was found that multiple PRP treatments reduced pain more than a single injection. This study evaluates the efficacy of multiple PRP (m-PRP) injections compared to multiple HA (m-HA) injections for KOA treatment, focusing on their correlation with PDGF-BB levels. (2) Methods: In this single-center, open-label, randomized, comparative clinical trial, 30 KOA patients received m-PRP and m-HA injections. VAS and WOMAC were used to evaluate clinical outcomes and PDGF-BB concentrations. (3) Results: The study analysis revealed a statistically significant reduction in pain indices. In both the m-PRP and m-HA groups after 12 weeks, m-PRP showed superior results. PDGF-BB concentrations also increased, with a strong negative correlation and statistical significance using Spearman's rho. (4) Conclusions: Multiple PRP injections are safe and associated with elevated PDGF-BB, reduced VAS and WOMAC scores, providing the potential for articular cartilage regeneration and inhibiting knee osteoarthritis progression.

Keywords: PDGF-BB; VAS; WOMAC; knee osteoarthritis; multiple intra-articular injections of hyaluronic acid; multiple intra-articular injections of platelet-rich plasma.

PubMed Disclaimer

Conflict of interest statement

The researchers and the hospital affirm that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Illustrates the procedure for producing PRP with two sets of centrifuges. (This illustration was designed and produced on the online platform Biorender.com, accessed on 1 January 2024).
Figure 2
Figure 2
Flowchart illustrating the process of screening, randomization, and determining the sample size for analysis.
Figure 3
Figure 3
Box diagram illustrating the treatment effect of m-PRP injection and m-HA injection measurements for week 12 before and after therapy. The clinical efficacy of the treatment was evaluated using two instruments: (A) the Visual Analogue Scale (VAS) and; (B) the Osteoarthritis Index of Western Ontario and McMaster University (WOMAC). a = Wilcoxon Test; b = Mann–Whitney Test, indicating whether the difference between pre- and post-evaluations is statistically significant (p < 0.05).
Figure 4
Figure 4
A correlation between increasing PDGF-BB levels and changes in VAS (A) and WOMAC scores (B). * Spearman’s rho test; ** p < 0.05. If the value of r = 0.0 to <0.2; very weak, r = 0.2 to <0.4; weak, r = 0.4 to <0.6; moderate, r = 0.6 to <0.8; strong, r = 0.8 to 1 = very strong.
Figure 5
Figure 5
The role of PDGF-BB in condrocytes in inhibiting the progression of KOA. →: Stimulate ⊣: inhibition (This illustration was designed and generated using the web platform Biorender.com, accessed on 1 January 2024).
See this image and copyright information in PMC

References

    1. Robinson W.H., Lepus C.M., Wang Q., Raghu H., Mao R., Lindstrom T.M., Sokolove J. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 2016;12:580–592. doi: 10.1038/nrrheum.2016.136. - DOI - PMC - PubMed
    1. Lv Z., Yang Y.X., Li J., Fei Y., Guo H., Sun Z., Lu J., Xu X., Jiang Q., Ikegawa S., et al. Molecular Classification of Knee Osteoarthritis. Front. Cell Dev. Biol. 2021;9:725568. doi: 10.3389/fcell.2021.725568. - DOI - PMC - PubMed
    1. Safiri S., Kolahi A.A., Smith E., Hill C., Bettampadi D., Mansournia M.A., Lu J., Xu X., Jiang Q., Ikegawa S., et al. Global, regional and national burden of osteoarthritis 1990–2017: A systematic analysis of the Global Burden of Disease Study 2017. Ann. Rheum. Dis. 2020;79:819–828. doi: 10.1136/annrheumdis-2019-216515. - DOI - PubMed
    1. Vos T., Allen C., Arora M., Barber R.M., Bhutta Z.A., Brown A., Carter A., Casey D.C., Charlson F.J., Chen A.Z., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. doi: 10.1016/S0140-6736(16)31678-6. - DOI - PMC - PubMed
    1. Di Cesare P.E., Haudenschild D.R., Samuels J., Abramson S.B. Pathogenesis of Osteoarthritis. In: Firestein G.S., Budd R.C., Gabriel S.E., McInnes I.B., O’Dell J.R., editors. Kelley’s Textbook of Rheumatology. 10th ed. Volume 2. Elsevier; Philadelphia, PA, USA: 2012. pp. 1617–1635. - DOI